m6A‐ and m5C‐ modified lncRNAs orchestrate the prognosis in cutaneous melanoma and m6A‐ modified LINC00893 regulates cutaneous melanoma cell metastasis

Author:

Shi Hao‐Ze1ORCID,Tian Cui‐Cui1ORCID,Wu Ming‐Yang1ORCID,Ma Li2,Sun Jian‐Fang1,Chen Hao1ORCID

Affiliation:

1. Institute of Dermatology Chinese Academy of Medical Sciences and Peking Union Medical College Nanjing China

2. Jiangsu Cancer Hospital and The Affiliated Cancer Hospital of Nanjing Medical University Nanjing China

Abstract

AbstractBackgroundAs the most important modifications on the RNA level, N6‐methyladenosine (m6A‐) and 5‐methylcytosine (m5C‐) modification could have a direct influence on the RNAs. Long non‐coding RNAs (lncRNAs) could also be modified by methylcytosine modification. Compared with mRNAs, the function of lncRNAs could be more potent to some extent in biological processes like tumorigenesis. Until now, rare reports have been done associated with cutaneous melanoma. Herein, we wonder if the m6A‐ and m5C‐ modified lncRNAs could influence the immune landscape and prognosis in melanoma, and we also want to find some lncRNAs which could directly affect the malignant behaviors of melanoma.MethodsSystematically, we explored the expression pattern of m6A‐ and m5C‐ modified lncRNAs in melanoma from datasets including UCSC Xena and NCBI GEO, and the prognostic lncRNAs were selected. Then, according to the expression pattern of lncRNAs, melanoma samples from these datasets were divided into several subtypes. Prognostic model, nomogram survival model, drug sensitivity, GO, and KEGG pathway analysis were performed. Furthermore, among several selected lncRNAs, we identified one lncRNA named LINC00893 and investigated its expression pattern and its biological function in melanoma cell lines.ResultsWe identified 27 m6A‐ and m5C‐ related lncRNAs which were significantly associated with survival, and we made a subtype analysis of melanoma samples based on these 27 lncRNAs. Among the two subtypes, we found differences of immune cells infiltration between these two subtypes. Then, LASSO algorithm was used to screen the optimized lncRNAs combination including ZNF252P‐AS1, MIAT, FAM13A‐AS1, LINC‐PINT, LINC00893, AGAP2‐AS1, OIP5‐AS1, and SEMA6A‐AS1. We also found that there was a significant correlation between the different risk groups predicted based on RS model and the actual prognosis. The nomogram survival model based on independent survival prognostic factors was also constructed. Besides, sensitivity to chemotherapeutic agents, GO and KEGG analysis were performed. In different risk groups, a total of 14 drug molecules with different distributions were obtained, which included AZD6482, AZD7762, AZD8055, camptothecin, dasatinib, erlotinib, gefitinib, gemcitabine, GSK269962A, nilotinib, rapamycin, and sorafenib. A total of 55 significantly related biological processes and 17 KEGG signaling pathways were screened. At last, we noticed that LINC00893 had a relatively lower expression in melanoma tissue and cell lines compared with adjacent tissues and epidermal melanocyte, and down‐regulation of LINC00893 could promote the malignant behavior of melanoma cells in A875 and MV3. In these two melanoma cell lines, down‐regulation of m6A‐related molecules like YTHDF3 and METTL3 could promote the expression of LINC00893.ConclusionWe made an analysis of m6A‐ and m5C‐ related lncRNAs in melanoma samples and a prediction of these lncRNAs’ role in prognosis, tumor microenvironment, immune infiltration, and clinicopathological features. We also found that LINC00893, which is potentially regulated by m6A modification, could serve as a tumor‐suppressor in melanoma and play an inhibitory role in melanoma metastasis.

Funder

Natural Science Foundation of Jiangsu Province

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3